289 related articles for article (PubMed ID: 34916092)
1. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.
Mehta K; Spaink HP; Ottenhoff THM; van der Graaf PH; van Hasselt JGC
Trends Pharmacol Sci; 2022 Apr; 43(4):293-304. PubMed ID: 34916092
[TBL] [Abstract][Full Text] [Related]
2. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
Hawn TR; Shah JA; Kalman D
Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy.
Mehta K; Guo T; Wallis RS; van der Graaf PH; van Hasselt JGC
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0036622. PubMed ID: 35862740
[TBL] [Abstract][Full Text] [Related]
4. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
5. Host factors subverted by
Kalra R; Tiwari D; Dkhar HK; Bhagyaraj E; Kumar R; Bhardwaj A; Gupta P
Int Rev Immunol; 2023; 42(1):43-70. PubMed ID: 34678117
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
[TBL] [Abstract][Full Text] [Related]
7. Host-directed therapy to combat mycobacterial infections.
Kilinç G; Saris A; Ottenhoff THM; Haks MC
Immunol Rev; 2021 May; 301(1):62-83. PubMed ID: 33565103
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
Leukes V; Walzl G; du Plessis N
Front Immunol; 2020; 11():451. PubMed ID: 32269568
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
Park HE; Lee W; Shin MK; Shin SJ
Front Immunol; 2021; 12():703060. PubMed ID: 34262571
[TBL] [Abstract][Full Text] [Related]
10. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment.
Kim YR; Yang CS
J Microbiol Biotechnol; 2017 Sep; 27(9):1549-1558. PubMed ID: 28683527
[TBL] [Abstract][Full Text] [Related]
11. Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis.
Saini S; Gangwar A; Sharma R
Microbiol Res; 2023 Oct; 275():127466. PubMed ID: 37531813
[TBL] [Abstract][Full Text] [Related]
12. Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances
Moreira JD; Koch BEV; van Veen S; Walburg KV; Vrieling F; Mara Pinto Dabés Guimarães T; Meijer AH; Spaink HP; Ottenhoff THM; Haks MC; Heemskerk MT
Front Immunol; 2020; 11():36. PubMed ID: 32117228
[TBL] [Abstract][Full Text] [Related]
13. Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections.
Heemskerk MT; Korbee CJ; Esselink JJ; Dos Santos CC; van Veen S; Gordijn IF; Vrieling F; Walburg KV; Engele CG; Dijkman K; Wilson L; Verreck FAW; Ottenhoff THM; Haks MC
Sci Rep; 2021 Oct; 11(1):19634. PubMed ID: 34608194
[TBL] [Abstract][Full Text] [Related]
14. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
Palucci I; Delogu G
Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
[TBL] [Abstract][Full Text] [Related]
15. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
Zumla A; Rao M; Dodoo E; Maeurer M
BMC Med; 2016 Jun; 14():89. PubMed ID: 27301245
[TBL] [Abstract][Full Text] [Related]
16. Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.
Zhao L; Fan K; Sun X; Li W; Qin F; Shi L; Gao F; Zheng C
Front Immunol; 2023; 14():1305325. PubMed ID: 38259491
[TBL] [Abstract][Full Text] [Related]
17. Effects of host-directed therapies on the pathology of tuberculosis.
Tsenova L; Singhal A
J Pathol; 2020 Apr; 250(5):636-646. PubMed ID: 32108337
[TBL] [Abstract][Full Text] [Related]
18. Modulating Iron for Metabolic Support of TB Host Defense.
Phelan JJ; Basdeo SA; Tazoll SC; McGivern S; Saborido JR; Keane J
Front Immunol; 2018; 9():2296. PubMed ID: 30374347
[TBL] [Abstract][Full Text] [Related]
19. Remembering the Host in Tuberculosis Drug Development.
Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.
Matteucci KC; Correa AAS; Costa DL
Front Cell Infect Microbiol; 2022; 12():905278. PubMed ID: 35669122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
